Virtus Biotech Clinical Trials Etf
Filed by ETFis Series Trust I. What this fund reported holding in its latest quarterly NPORT-P. Positions are ordered by share of the fund rather than by size, because that is what separates a conviction from a rounding error.
What it holds
Largest share of the fund first.
| Company | % of fund | Value |
|---|---|---|
| AMLXAmylyx Pharmaceuticals Inc | 0.93% | $432.7K |
| RLAYRelay Therapeutics Inc | 0.85% | $395.2K |
| KODKodiak Sciences Inc | 0.82% | $379.4K |
| NKTRNektar Therapeutics | 0.80% | $369.9K |
| COGTCogent Biosciences Inc | 0.79% | $365.6K |
| PRAXPraxis Precision Medicines Inc | 0.77% | $358.9K |
| PCVXVaxcyte Inc | 0.76% | $354.2K |
| GPCRStructure Therapeutics Inc | 0.75% | $347.8K |
| CMPSCompass Pathways PLC | 0.63% | $292K |
| TECXTectonic Therapeutic, Inc. - Common Stock | 0.62% | $287.7K |
| NTLAIntellia Therapeutics Inc | 0.59% | $274.1K |
| RLMDRelmada Therapeutics Inc | 0.53% | $248.2K |
Source: NPORT-P filings, via EDGAR. Positions arrive by CUSIP, and only a CUSIP verified against a ticker is kept — so this is what we could match, not everything the fund holds, and the matched value is therefore below the fund's own size. A balance is shares where the filing says `NS` and a principal amount where it says `PA`, which is why it is not labelled shares in both cases.
Follow Virtus Biotech Clinical Trials Etf by email
Virtus Biotech Clinical Trials Etf's new holdings reports, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.